Preview Citation

Grabowski, H., & Lietzan, E. (2015-09-29). FDA Regulation of Biosimilars. In FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies. : Columbia University Press. Retrieved 5 Jul. 2022, from https://columbia.universitypressscholarship.com/view/10.7312/columbia/9780231171182.001.0001/upso-9780231171182-chapter-29.

Grabowski, Henry, and Erika Lietzan. "FDA Regulation of Biosimilars." FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies. : Columbia University Press,  19. Columbia Scholarship Online. Date Accessed 5 Jul. 2022 <https://columbia.universitypressscholarship.com/view/10.7312/columbia/9780231171182.001.0001/upso-9780231171182-chapter-29>.

Grabowski, Henry, and Erika Lietzan. "FDA Regulation of Biosimilars." In FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies, edited by Holly Fernandez Lynch, and I. Glenn Cohen. Columbia University Press, 2015. Columbia Scholarship Online, 2016. doi: 10.7312/columbia/9780231171182.003.0029.

Grabowski H, Lietzan E. FDA Regulation of Biosimilars. In: FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies. Columbia University Press; 2015. https://columbia.universitypressscholarship.com/view/10.7312/columbia/9780231171182.001.0001/upso-9780231171182-chapter-29. Accessed July 5, 2022.